Reparixin - CAS# 266359-83-5 10125 Ocular hypotensive efficacy

Ocular hypotensive efficacy

Formula: C18H14Cl2N2O2

PubMed PMID: 20213763

2R)-1-hydroxy-1-phenylpropan-2-yl]carbamoyl}-1-methoxy-2-methylethyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)carbamoyl}-2-methylpropyl]carbamoyl}-2-methylpropyl]-N-methylhexanamide

S-Ruxolitinib is a less active enantiomer of Ruxolitinib

Reparixin - CAS# 266359-83-5 10125 Ocular hypotensive efficacyReparixin is an inhibitor of CXCR2 function, which attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord. In a human breast cancer cell line, both reparixin reduced the number of breast cancer stem cells compared with no treatment. I n mice with primary human breast cancer xenografts, reparixin alone or in combination with docetaxel reduced tumor growth compared with saline control. The